Over-expression of ROR2 and Wnt5a Cooperatively Correlates with Unfavorable Prognosis in Patients with Non-small Cell Lung Cancer

Overview

Journal Oncotarget

Specialty Oncology

Date 2015 Aug 26

PMID 26305508

Citations 30

Authors

Chenlin Lu

Xudong Wang

Huijun Zhu

Jian Feng

Songshi Ni

Jianfei Huang

Affiliations

Soon will be listed here.

Abstract

We investigated the expression of receptor tyrosine kinase-like orphan receptor (ROR) 2 and Wnt5a and their prognostic significance in non-small cell lung cancer (NSCLC). Tissue microarray-based immunohistochemical analysis was performed to determine the expression of ROR2 and Wnt5a in 219 patients. mRNA expression of ROR2 and Wnt5a was examined in 20 pairs of NSCLC and matched adjacent normal tissues by real-time PCR. Compared with non-tumorous tissues, both mRNA expression and protein product of ROR2 and Wnt5a genes were significantly increased in NSCLC. c2 analysis revealed that high ROR2 or Wnt5a expression in NSCLC was significantly associated with advanced TNM stage. High expression of both ROR2 and Wnt5a was also related to advanced TNM stage. Multivariate analyses suggested that ROR2, Wnt5a and TNM stage were independent prognostic factors in NSCLC. Our clinical findings suggest that high ROR2 or Wnt5a expression is associated with poor prognosis in NSCLC, and combined detection of ROR2 and Wnt5a is helpful in predicting the prognosis of NSCLC.

Citing Articles

WISP1 and Macrophage Migration Inhibitory Factor in Respiratory Inflammation: Novel Insights and Therapeutic Potentials for Asthma and COPD.

Christopoulou M, Aletras A, Papakonstantinou E, Stolz D, Skandalis S Int J Mol Sci. 2024; 25(18).

PMID: 39337534 PMC: 11432718. DOI: 10.3390/ijms251810049.

Exploring the Potential of Antibody-Drug Conjugates in Targeting Non-small Cell Lung Cancer Biomarkers.

Khadela A, Megha K, Shah V, Soni S, Shah A, Mistry H Clin Med Insights Oncol. 2024; 18:11795549241260534.

PMID: 38911453 PMC: 11193349. DOI: 10.1177/11795549241260534.

The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy.

Liu X, Deng J, Zhang R, Xing J, Wu Y, Chen W Front Immunol. 2024; 14:1335252.

PMID: 38162667 PMC: 10755013. DOI: 10.3389/fimmu.2023.1335252.

WNT ligands in non-small cell lung cancer: from pathogenesis to clinical practice.

Xue W, Cai L, Li S, Hou Y, Wang Y, Yang D Discov Oncol. 2023; 14(1):136.

PMID: 37486552 PMC: 10366069. DOI: 10.1007/s12672-023-00739-7.

Role of ROR2 in promoting gastric cancer metastasis by enhancing c-JUN-mediated MMP3 transcription.

Ge X, Lin F, Wu Z, Lin Y, Tang W, McKay M Ann Transl Med. 2022; 10(20):1117.

PMID: 36388837 PMC: 9652548. DOI: 10.21037/atm-22-4583.

References

OConnell M, Fiori J, Xu M, Carter A, Frank B, Camilli T . The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma. Oncogene. 2009; 29(1):34-44. PMC: 2803338. DOI: 10.1038/onc.2009.305. View

Rasmussen N, Wright T, Brooks S, Hacker K, Debebe Z, Sendor A . Receptor tyrosine kinase-like orphan receptor 2 (Ror2) expression creates a poised state of Wnt signaling in renal cancer. J Biol Chem. 2013; 288(36):26301-26310. PMC: 3764835. DOI: 10.1074/jbc.M113.466086. View

Enomoto M, Hayakawa S, Itsukushima S, Ren D, Matsuo M, Tamada K . Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling. Oncogene. 2009; 28(36):3197-208. DOI: 10.1038/onc.2009.175. View

Serra R, Easter S, Jiang W, Baxley S . Wnt5a as an effector of TGFβ in mammary development and cancer. J Mammary Gland Biol Neoplasia. 2011; 16(2):157-67. PMC: 3107509. DOI: 10.1007/s10911-011-9205-5. View

Kobayashi M, Shibuya Y, Takeuchi J, Murata M, Suzuki H, Yokoo S . Ror2 expression in squamous cell carcinoma and epithelial dysplasia of the oral cavity. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009; 107(3):398-406. DOI: 10.1016/j.tripleo.2008.08.018. View

Geng M, Cao Y, Chen Y, Jiang H, Bi L, Liu X . Loss of Wnt5a and Ror2 protein in hepatocellular carcinoma associated with poor prognosis. World J Gastroenterol. 2012; 18(12):1328-38. PMC: 3319959. DOI: 10.3748/wjg.v18.i12.1328. View

Wright T, Brannon A, Gordan J, Mikels A, Mitchell C, Chen S . Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma. Oncogene. 2009; 28(27):2513-23. PMC: 2771692. DOI: 10.1038/onc.2009.116. View

Angers S, Moon R . Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol. 2009; 10(7):468-77. DOI: 10.1038/nrm2717. View

Billiard J, Way D, Seestaller-Wehr L, Moran R, Mangine A, Bodine P . The orphan receptor tyrosine kinase Ror2 modulates canonical Wnt signaling in osteoblastic cells. Mol Endocrinol. 2004; 19(1):90-101. DOI: 10.1210/me.2004-0153. View

10.

Oishi I, Suzuki H, Onishi N, Takada R, Kani S, Ohkawara B . The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt5a/JNK signalling pathway. Genes Cells. 2003; 8(7):645-54. DOI: 10.1046/j.1365-2443.2003.00662.x. View

11.

Shih J, Yang P . The EMT regulator slug and lung carcinogenesis. Carcinogenesis. 2011; 32(9):1299-304. DOI: 10.1093/carcin/bgr110. View

12.

Dale T . Signal transduction by the Wnt family of ligands. Biochem J. 1998; 329 ( Pt 2):209-23. PMC: 1219034. DOI: 10.1042/bj3290209. View

13.

You Z, Saims D, Chen S, Zhang Z, Guttridge D, Guan K . Wnt signaling promotes oncogenic transformation by inhibiting c-Myc-induced apoptosis. J Cell Biol. 2002; 157(3):429-40. PMC: 2173296. DOI: 10.1083/jcb.200201110. View

14.

Herzlinger D, Qiao J, Cohen D, Ramakrishna N, Brown A . Induction of kidney epithelial morphogenesis by cells expressing Wnt-1. Dev Biol. 1994; 166(2):815-8. DOI: 10.1006/dbio.1994.1360. View

15.

Li C, Chen H, Hu L, Xing Y, Sasaki T, Villosis M . Ror2 modulates the canonical Wnt signaling in lung epithelial cells through cooperation with Fzd2. BMC Mol Biol. 2008; 9:11. PMC: 2254434. DOI: 10.1186/1471-2199-9-11. View

16.

Reckamp K . Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer. Cancer Lett. 2012; 321(2):101-9. DOI: 10.1016/j.canlet.2012.01.041. View

17.

Huang C, Liu D, Nakano J, Ishikawa S, Kontani K, Yokomise H . Wnt5a expression is associated with the tumor proliferation and the stromal vascular endothelial growth factor--an expression in non-small-cell lung cancer. J Clin Oncol. 2005; 23(34):8765-73. DOI: 10.1200/JCO.2005.02.2871. View

18.

Kremenevskaja N, von Wasielewski R, Rao A, Schofl C, Andersson T, Brabant G . Wnt-5a has tumor suppressor activity in thyroid carcinoma. Oncogene. 2005; 24(13):2144-54. DOI: 10.1038/sj.onc.1208370. View

19.

Cheng R, Sun B, Liu Z, Zhao X, Qi L, Li Y . Wnt5a suppresses colon cancer by inhibiting cell proliferation and epithelial-mesenchymal transition. J Cell Physiol. 2014; 229(12):1908-17. DOI: 10.1002/jcp.24566. View

20.

Jiang W, Crossman D, Mitchell E, Sohn P, Crowley M, Serra R . WNT5A inhibits metastasis and alters splicing of Cd44 in breast cancer cells. PLoS One. 2013; 8(3):e58329. PMC: 3590134. DOI: 10.1371/journal.pone.0058329. View